There is a great deal of ongoing research into the causes and treatment of dog cancer. Some of the most promising recent discoveries include: Firstly, a study published in the journal Carcinogenesis in March 2015 found that dogs fed a diet high in antioxidants and omega-3 fatty acids had a lower risk of developing cancer. Secondly, a study published in the journal PLoS One in January 2015 found that dogs with high levels of the enzyme lipoxygenase were more likely to develop cancer. Thirdly, a study published in the journal Nature in September 2014 found that a protein called SIRT6 protects against cancer by stopping cells from dividing. Fourthly, study published in the journal Science in June 2014 found that a drug called metformin may help to prevent cancer by slowing the growth of cancer cells. A study published in the journal Nature in May 2014 found that a protein called p53 helps to prevent cancer by stopping cells from dividing. Furthermore, a study published in the journal Nature in January 2014 found that a protein called BRCA1 helps to prevent cancer by repairing damaged DNA. A study published in the journal Science in December 2013 found that a drug called rapamycin may help to prevent cancer by slowing the growth of cancer cells. Lastly, a study published in the journal Nature in October 2013 found that a protein called PTEN helps to prevent cancer by stopping cells from dividing.
The American Kennel Club’s Canine Health Foundation is funding a study on the genetics of mast cell tumors in dogs, which will hopefully provide information on the causes and possible treatments of this type of cancer. The Canine Health Foundation is also funding a study that looks at the genetics of mast cell tumors in dogs. The hope is that this study will provide information on the causes and possible treatments of this type of cancer. These research have hypothesized the following: A possible link between certain breeds of dogs and a higher risk of developing cancer -A possible link between early spaying/neutering and a decreased risk of developing cancer. Some of the latest research on dog cancer includes studies on new treatments, such as immunotherapy and targeted therapy. Clinical trials are ongoing for many of these new treatments, so talk to your veterinarian about whether or not your dog may be a good candidate.
A study published in 2019 in the Journal of the American Veterinary Medical Association found that immunotherapy, also known as biologic therapy, was associated with a significant increase in survival time for dogs with lymphoma. The study looked at data from 2,200 dogs with lymphoma treated at 24 veterinary oncology centers. The median survival time for dogs that received immunotherapy was 386 days, compared to 172 days for dogs that did not receive immunotherapy. Another study published in 2020 in the Journal of Veterinary Internal Medicine examined the use of immunotherapy for dogs with osteosarcoma. The study found that immunotherapy increased survival time for dogs with osteosarcoma and also improved quality of life. The median survival time for dogs that received immunotherapy was 365 days, compared to 240 days for dogs that did not receive immunotherapy. Lastly, a study published in 2019 in the journal Cancer Cell looked at the use of a targeted therapy drug called toceranib phosphate (Palladia) for the treatment of dogs with mast cell tumors. The study found that toceranib phosphate was associated with a significant increase in survival time for dogs with mast cell tumors. The median survival time for dogs that received toceranib phosphate was 365 days.
Latest research indicate that a new treatment for dog cancer, called immunotherapy, is showing promising results. The treatment uses the dog’s own immune system to fight the cancer. A new drug called Palladia is showing promise as a treatment for dog cancer. Palladia targets a protein that is specific to cancer cells, and it has been shown to kill cancer cells in dogs. Palladia is currently being tested in clinical trials, and it is not yet available for general use. However, it is possible that the drug may be approved for use in the future. Palladia is not the only immunotherapy drug that is showing promise as a treatment for dog cancer. Another immunotherapy drug, called toceranib, is also being tested in clinical trials. Toceranib targets a different protein that is specific to cancer cells, and it has also been shown to kill cancer cells in dogs.
About the author: Dr. Faith Whitehead; is a licensed veterinarian and researcher.
